-
-
-
-
-
-
-
FDA accepts BioXcel Therapeutics application for at-home IGALMI use
-
-
-
-
-
-
-
BioXcel Therapeutics (BTAI) Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders
-
-
-
-
-
-
-
BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
-
-
-
-
-
15,422 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

